May 27 (Reuters) - Mithra Pharmaceuticals SA MITRA.BR :
- NEXTSTELLIS RECEIVES FDA MARKETING EXCLUSIVITY AND PHASE III DATA PUBLISHED
- EXCLUSIVITY RUNS FOR FIVE YEARS FROM FDA APPROVAL OF THE NEW DRUG APPLICATION FOR NEXTSTELLIS
Source text: https://bit.ly/3wB8Nfp
News: MYX Mithra, Mayne Pharma's Nextstellis Receives FDA Marketing Exclusivity
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.15 |
Change
0.130(2.59%) |
Mkt cap ! $418.4M | |||
| Open | High | Low | Value | Volume |
| $5.05 | $5.17 | $5.05 | $571.9K | 111.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $5.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.17 | 490 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |